CJC-1295 vs Sermorelin (2026): GHRH Analog Research Comparison

CJC-1295 and Sermorelin are two of the most-confused names in the growth-hormone-secretagogue corner of the research-peptide market. They sit in the same class — GHRH analogs — act on the same receptor, and are studied for overlapping research questions. The decision between them is driven almost entirely by one variable: how long the molecule stays active. This article compares them on structure, the all-important DAC distinction, pulsatility, evidence, and what the half-life gap means for protocol design and sourcing. Everything below is framed for laboratory research use only.

Same class, same receptor

Both compounds are analogs of growth-hormone-releasing hormone (GHRH), the endogenous hypothalamic peptide that stimulates the pituitary to secrete growth hormone. Both act on the GHRH receptor — a cell-surface G-protein-coupled receptor on pituitary somatotrophs. That shared mechanism is why they are reasoned about together and why the comparison is meaningful in the first place.

This is also why GHRH analogs are a distinct class from GHRPs (growth-hormone-releasing peptides, such as Ipamorelin), which act on the separate ghrelin/GHS receptor. We unpack that class boundary in GHRP vs GHRH explained; for this article, the key point is that CJC-1295 and Sermorelin are on the same side of that line.

The structural difference

Sermorelin is GRF(1-29) — the first 29 amino acids of GHRH, the shortest fragment that retains full receptor activity. It is, in effect, the minimal functional GHRH analog. Its defining property is a very short half-life: it is cleared rapidly, producing a brief, sharp signal.

CJC-1295 is a modified GHRH(1-29) analog engineered for greater enzymatic stability through amino-acid substitutions that resist degradation. From there it splits into two functionally distinct compounds:

• CJC-1295 without DAC (often labeled mod-GRF 1-29) — a stabilized short-acting analog, longer-lived than Sermorelin but still relatively brief.
• CJC-1295 with DAC — carries a Drug Affinity Complex, a maleimide group that binds covalently to circulating serum albumin, dramatically extending half-life from minutes to a far longer window.

Half-life is the whole comparison

Strip away the names and the difference between these compounds is duration of action.

This matters because the pituitary's growth-hormone axis is pulsatile — endogenous secretion comes in discrete bursts, and the timing of a stimulus relative to those natural pulses is a studied variable. A short-acting analog like Sermorelin produces a signal that more closely tracks the natural pulse; a DAC-extended analog produces sustained receptor engagement that departs from the pulsatile pattern. Neither is "better" in the abstract — they answer different research questions, and the choice should follow the question, not convenience. Our explainer on peptide half-life and timing covers why pulsatility makes timing central for this whole class.

Evidence base

As with any compound, evidence lives at the molecule level, not the class level. Sermorelin has the longer regulatory and clinical history of the two as a human compound, which means more published characterization of its short-acting kinetics. CJC-1295 — particularly the DAC variant — is the newer engineering effort, studied largely in the research-compound context for its extended-duration profile. The research-grade material for both is sold for laboratory use only, and neither should be evaluated through the lens of human outcomes.

Because CJC-1295 is the compound in our catalog, you can review its documented mechanism in the peptide reference library and in the dedicated profile for the CJC-1295 / Ipamorelin pairing, which is how CJC-1295 most commonly appears in research-peptide supply. Sermorelin is referenced here as literature context only.

Sourcing and verification

The verification logic is the same for any research peptide: never trust a label, demand documentation. For either compound, insist on a batch-specific Certificate of Analysis with HPLC purity and mass-spec identity confirmation from a named third-party lab. Two compound-specific cautions for this class:

• Confirm the DAC status. Because "CJC-1295" spans two kinetically different compounds, the identity confirmation on the COA matters more than usual. Mislabeling the DAC variant is a known failure mode in the research-peptide market.
• Both are temperature-sensitive lyophilized peptides reconstituted in bacteriostatic water, so cold-chain handling and disciplined storage apply.

For compound-specific buying guidance and which vendors cleared it, see the where-to-buy guide for CJC-1295 / Ipamorelin, and for related sourcing across the secretagogue class, our CJC-1295 / Ipamorelin buyer's guide and the 2026 supplier evaluation.

Bottom line

CJC-1295 and Sermorelin are GHRH analogs acting on the same receptor; the comparison between them is essentially a comparison of half-life. Sermorelin is the minimal short-acting fragment (GRF 1-29); CJC-1295 is a stabilized analog that, in its DAC form, binds albumin for markedly extended action. The most important practical caveat is internal to CJC-1295 itself: the DAC and no-DAC versions are different compounds, and confirming which one is in the vial is a verification step, not a footnote. As always, the useful question is not "which is better" but "what exactly is this compound, what does its literature show, and can I verify it." For the verification half, see our compound buying guides and the where-to-buy index.

For research use only. This content is informational and does not constitute medical, legal, or dosing advice. All compounds referenced are for laboratory research use only — not for human consumption.

Disclosure: Peptide Research Review maintains affiliate relationships with some of the suppliers we reference. Affiliate status has no influence on our research framing or our blinded, third-party lab evaluations. Read our editorial policy and methodology.